Aflibercept (Eylea®) and Biosimilars

Aflibercept is a biologic drug product that is launched by Regeneron Pharmaceuticals and is approved for medical use in the United States and the European Union. This drug is originally sold under the brand name Eylea®. Aflibercept is a fully human recombinant fusion protein that includes domains of both VEGFR-1 and -2 fused to the Fc region of human IgG1. Aflibercept acts as a soluble decoy receptor that binds to VEGF-A, VEGF-B and placental growth factor (PIGF) that essentially renders the VEGF-A and PlGF ligands unable to bind and activate cell receptors. This drug has been used in the treatment of wet macular degeneration and metastatic colorectal cancer. Yesafili is the first aflibercept biosimilar that was developed by Biocon Biologics and has been approved by the European Commission.

RGBiotech offers pcDNA3.1-Aflibercept(Neo) plasmid vector for overexpressing Aflibercept in mammalian expression system in order to assist your biosimilar research and development.

Product Name: pcDNA3.1-Aflibercept(Neo) Plasmid Vector

Item No.: PPBD-4-1

Plasmid Vector Map:

Quality Control:

Contact Us